Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

James Kelley MD PhD Has Accepted the Role of CMO at OneOme

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

James Kelley MD, PhD has accepted the role of Chief Medical Officer (CMO) of OneOme. In this role, he will lead OneOme’s Medical functions including Medical Affairs and Laboratory Operations.

James Kelley MD, PhD will also serve as OneOme’s overall executive in charge of all medical and clinical policies and procedures as well as all external affairs with federal, state and international regulatory agencies as it relates to all medical matters.

“I am excited to join OneOme – a leader in the pharmacogenomics field. As a physician and as a patient who has experienced adverse drug reactions, I know both the positive and negative impacts drugs can have. Providing doctors with the best available information when selecting medications for an individual patient has great potential to reduce the risk in patient care.”

Co-founded by Mayo Clinic, OneOme is a Minneapolis, Minnesota-based precision medicine company focused on bringing high-quality pharmacogenomics (PGx) into patient care. With a belief that PGx holds the potential to make a positive, appreciable difference in the lives of patients, OneOme works closely with their partners to help realize these benefits across the healthcare ecosystem.

James Kelley is a physician-scientist board certified in Clinical Pathology (laboratory medicine), Transfusion Medicine (blood banking), Clinical Informatics, Medical Quality, and Regulatory Affairs. He earned his PhD in Immunology and Informatics from the University of Cambridge, his MD from the University of Alabama, and a MS in Healthcare Management from Johns Hopkins University. James completed his residency and fellowship at Harvard Medical School and completed postdoctoral research fellowships in Genomics and Stem Cell Biology resulting in dozens of peer reviewed publications. He was on faculty at The University of Texas MD Anderson Cancer Center, leading laboratory quality and serving as CLIA director of a clinical laboratory performing 14 million tests per year. He has been principal investigator of numerous industry-sponsored clinical trials and most recently worked in research and development at Terumo Blood and Cell Technologies. James is a fellow of the College of American Pathologists having advocated payment policy, reimbursement, and quality measurement as well as leading lab accreditation teams. He has volunteered for NGOs dedicated to global health efforts and traveled to over 120 countries.

As OneOme welcomes Dr. Kelley to his role, Dr. Julie England will resume her role of Medical Director of Medical Affairs. During the interim, Dr. England kept the CMO office operating at full capacity and with the highest of integrity, and has been instrumental in supporting Lab leadership and growth. Dr. England said, “I have enjoyed filling the interim role of CMO at OneOme during the executive search. Dr. Kelley’s background is an excellent fit for OneOme and I look forward to working with him and continuing to lead the Medical Affairs team into the future.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine